These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 30216402)

  • 1. CV risk prediction tools: Imperfect, Yes, but are they serviceable?
    Firnhaber JM
    J Fam Pract; 2018 Sep; 67(9):E3-E8. PubMed ID: 30216402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses.
    Garg N; Muduli SK; Kapoor A; Tewari S; Kumar S; Khanna R; Goel PK
    Indian Heart J; 2017; 69(4):458-463. PubMed ID: 28822511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cholesterol and statin controversy: the new 2013 statin-cholesterol guidelines.
    Sinatra ST; Teter BB; Bowden J; Houston MC; Martinez-Gonzalez MA
    Altern Ther Health Med; 2014; 20(5):14-7. PubMed ID: 25141366
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparing Guidelines for Statin Treatment in Canada and the United States.
    Hennessy DA; Bushnik T; Manuel DG; Anderson TJ
    J Am Heart Assoc; 2015 Jul; 4(7):. PubMed ID: 26175357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canadian data provide window on statin use.
    Brown C
    CMAJ; 2016 Mar; 188(5):325. PubMed ID: 26903356
    [No Abstract]   [Full Text] [Related]  

  • 6. Time to improve statin prescription guidelines in low-risk patients?
    Balder JW; de Vries JK; Mulder DJ; Kamphuisen PW
    Eur J Prev Cardiol; 2017 Jul; 24(10):1064-1070. PubMed ID: 28429651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of Cardiovascular Disease Risk Accounting for Future Initiation of Statin Treatment.
    Xu Z; Arnold M; Stevens D; Kaptoge S; Pennells L; Sweeting MJ; Barrett J; Di Angelantonio E; Wood AM
    Am J Epidemiol; 2021 Oct; 190(10):2000-2014. PubMed ID: 33595074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of 3 risk estimators to guide initiation of statin therapy for primary prevention of cardiovascular disease.
    Ofori S; Dodiyi-Manuel S; Akpa MR
    J Clin Lipidol; 2017; 11(6):1441-1447. PubMed ID: 29050979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACP Journal Club. ACC/AHA, Adult Treatment Panel III, and ESC guidelines overestimated risk for CVD in older adults.
    Vaishnava P; Eagle KA
    Ann Intern Med; 2014 Aug; 161(4):JC13. PubMed ID: 25133380
    [No Abstract]   [Full Text] [Related]  

  • 10. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease.
    Robson J
    Heart; 2008 Oct; 94(10):1331-2. PubMed ID: 18701534
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease based on available randomised clinical trial evidence: The Rotterdam Study.
    Pavlović J; Greenland P; Deckers JW; Kavousi M; Hofman A; Ikram MA; Franco OH; Leening MJ
    Eur J Prev Cardiol; 2018 Mar; 25(4):420-431. PubMed ID: 29171772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the role of big data in the CV risk calculator controversy.
    Smith A
    Am J Manag Care; 2014 Jan; 20(1 Spec No.):E1. PubMed ID: 25618227
    [No Abstract]   [Full Text] [Related]  

  • 13. Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.
    Arca M; Ansell D; Averna M; Fanelli F; Gorcyca K; Iorga ŞR; Maggioni AP; Paizis G; Tomic R; Catapano AL
    Atherosclerosis; 2018 Apr; 271():120-127. PubMed ID: 29499359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of the 2014 NICE cholesterol guidelines in the English population: a cross-sectional analysis.
    Ueda P; Lung TW; Clarke P; Danaei G
    Br J Gen Pract; 2017 Sep; 67(662):e598-e608. PubMed ID: 28760741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The new pooled cohort equations risk calculator.
    Preiss D; Kristensen SL
    Can J Cardiol; 2015 May; 31(5):613-9. PubMed ID: 25843167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ambivalence about the selection of cardiovascular risk stratification tools: Evidence in a type 1 diabetes population.
    Bovi TG; Zantut-Wittmann DE; Parisi MCR
    Diabetes Metab Syndr; 2019; 13(3):2322-2327. PubMed ID: 31235175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins: new US guideline sparks controversy.
    Lancet; 2013 Nov; 382(9906):1680. PubMed ID: 24267985
    [No Abstract]   [Full Text] [Related]  

  • 18. New AHA-ACC guidelines could lead to major changes in clinical practice.
    Rosenberg K
    Am J Nurs; 2014 Feb; 114(2):13. PubMed ID: 24481346
    [No Abstract]   [Full Text] [Related]  

  • 19. Achieving vascular risk factor targets: a survey of a London general practice.
    Levine AP; Mikhailidis DP; Moross T; Benson K; Gor M
    Angiology; 2008; 59(1):36-46. PubMed ID: 18319220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy.
    Begovac J; Dragović G; Višković K; Kušić J; Perović Mihanović M; Lukas D; Jevtović Đ
    Croat Med J; 2015 Feb; 56(1):14-23. PubMed ID: 25727038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.